Related stories
Core Scientific Posts Q3 EPS of $0.47
Core Scientific reported Q3 EPS of $0.47, versus FactSet’s estimate of a $0.05 loss.
M impact | EQUITY | Nov 05, 2026, 12:11 PM UTC
Precision BioSciences Prices $125 Million Stock and Warrant Offering
M impact | EQUITY | Nov 05, 2026, 12:11 PM UTC
Akebia Therapeutics Reports Third-Quarter 2026 Results
Akebia said patients on Vafseo (vadadustat) increased to approximately 11,500 at the end of Q3 2026.
M impact | EQUITY | Nov 05, 2026, 12:11 PM UTC
Nexstar Reports Q3 Revenue of $2.13 Billion, Above FactSet Estimate
Nexstar reported Q3 revenue of $2.13 billion, versus a FactSet estimate of $2.07 billion.
M impact | EQUITY | Nov 05, 2026, 12:10 PM UTC
Iovance Biotherapeutics reports Q3 revenue of $121.5 million
Iovance reported Q3 revenue of $121.5 million, versus a FactSet estimate of $116.0 million.
M impact | EQUITY | Nov 05, 2026, 12:10 PM UTC
Frontdoor Expects Q4 Revenue of $453M-$463M
M impact | EQUITY | Nov 05, 2026, 12:10 PM UTC